CTLA4 and neoplasm: Recently, immunotherapy based on the inhibition of immune checkpoint (IC) molecules, most notably of the programmed cell death receptor (PD)-1 and cytotoxic T lymphocyte antigen (CTLA)-4, has shown potential to enhance immune response against tumor cells and thereby modulate TME [12,13].